Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019

被引：8
|
作者：
Kherabi, Yousra [1 ]
Frechet-Jachym, Mathilde [3 ]
Rioux, Christophe [1 ,4 ]
Yazdanpanah, Yazdan [1 ,2 ,4 ,5 ,6 ]
Mechai, Frederic [7 ,8 ]
Pourcher, Valerie [9 ]
Robert, Jerome [2 ,10 ]
Guglielmetti, Lorenzo [2 ,10 ]
机构：
[1] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Paris, France
[2] Sorbonne Univ, INSERM, U1135, Paris, France
[3] Ctr Hosp Bligny, Briis Sous Forges, France
[4] Assistance Publ Hop Paris, Paris, France
[5] Univ Paris, INSERM, IAME, Paris, France
[6] Univ Paris Diderot, Paris, France
[7] Hop Avicenne, Assistance Publ Hop Paris, Paris, France
[8] Hop Avicenne, Bobigny, France
[9] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
[10] Sorbonne Univ, Hop Pitie Salpetriere, Assistance Publ Hop Paris, Paris, France
来源：
EMERGING INFECTIOUS DISEASES | 2022年 / 28卷 / 09期
关键词：
CULTURE CONVERSION; XDR-TB; FLUOROQUINOLONES; TOLERABILITY; SAFETY; IMPACT;
D O I：
10.3201/eid2809.220458
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France. The study included 298 patients treated for MDR TB at 3 reference centers during 2006-2019. Of those, 205 (68.8%) cases were fluoroquinolone-susceptible MDR TB and 93 (31.2%) were preXDR/XDR TB. Compared with fluoroquinolone-susceptible MDR TB, pre-XDR/XDR TB was associated with more cavitary lung lesions and bilateral disease and required longer treatment. Overall, 202 patients (67.8%) had favorable treatment outcomes, with no significant difference between pre-XDR/XDR TB (67.7%) and fluoroquinolone-susceptible MDR TB (67.8%; p = 0.99). Pre-XDR/XDR TB was not associated with higher risk for serious adverse events.
引用
收藏
页码：1796 / 1804
页数：9
相关论文
共 50 条
  • [21] Association Of Tuberculosis Pyrazinamide Resistance With Treatment Outcomes In San Francisco, California
    Budzik, J. M.
    Nahid, P.
    Hopewell, P. C.
    Kato-Maeda, M.
    Higashi, J.
    Grinsdale, J.
    Jarlsberg, L. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [22] Pharmacokinetic Variability and Tuberculosis Treatment Outcomes, Including Acquired Drug Resistance
    Egelund, Eric F.
    Peloquin, Charles A.
    CLINICAL INFECTIOUS DISEASES, 2012, 55 (02) : 178 - 179
  • [23] Potential Predictors of Unsuccessful Treatment Outcomes of Multiple Drug Resistance Tuberculosis in Program Management Drug Resistance Tuberculosis Setting
    Khalid, Wahab
    Hamid, Husnain
    Naveed, Rabia
    Baig, Taimoor Hassan Khan
    Masood, Rizwan Ali
    Tariq, Hira
    Pervaiz, Ayesha
    Mehmood, Arshad
    LATIN AMERICAN JOURNAL OF PHARMACY, 2020, 39 (10): : 1977 - 1982
  • [24] Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008–2019: a retrospective analysis
    Keatlaretse Siamisang
    Goabaone Rankgoane-Pono
    Tumisang Malebo Madisa
    Tantamika Kabamba Mudiayi
    John Thato Tlhakanelo
    Paul Mubiri
    Khutsafalo Kadimo
    Francis Msume Banda
    Vincent Setlhare
    BMC Public Health, 22
  • [25] How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform? Reply
    Bastard, Mathieu
    Bonnet, Maryline
    du Cros, Philipp
    Khamraev, Atadjan Karimovich
    Hayrapetyan, Armen
    Kimenye, Kamene
    Khurkhumal, Shazina
    Dlamini, Themba
    Telnov, Alex
    Sanchez-Padilla, Elisabeth
    Hewison, Cathy
    Varaine, Francis
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (01) : 117 - 118
  • [26] Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
    Bachir, Marwa
    Guglielmetti, Lorenzo
    Tunesi, Simone
    Billard-Pomares, Typhaine
    Chiesi, Sheila
    Jaffre, Jeremy
    Langris, Hugo
    Pourcher, Valerie
    Schramm, Frederic
    Lemaitre, Nadine
    Robert, Jerome
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 107 : 86 - 91
  • [27] Evaluating tuberculosis treatment outcomes in Haiti from 2018 to 2019: A competing risk analysis
    Raphael, Nernst-Atwood
    Garraud, Pierre Anthony
    Roelens, Maroussia
    Alfred, Jean Patrick
    Richard, Milo
    Estill, Janne
    Keiser, Olivia
    Merzouki, Aziza
    IJID REGIONS, 2024, 11
  • [28] Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens (vol 23, pg 619, 2019)
    Schwoebel, V.
    Chiang, C-Y.
    Trebucq, A.
    Piubello, A.
    Ait-Khaled, N.
    Koura, K. G.
    Heldal, E.
    Van Deun, A.
    Rieder, H. L.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (07) : 876 - 876
  • [29] Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe
    Karo, Basel
    Kohlenberg, Anke
    Hollo, Vahur
    Duarte, Raquel
    Fiebig, Lena
    Jackson, Sarah
    Kearns, Cathriona
    Kodmon, Csaba
    Korzeniewska-Kosela, Maria
    Papaventsis, Dimitrios
    Solovic, Ivan
    Van Soolingen, Dick
    van der Werf, Marieke
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [30] Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008-2019: a retrospective analysis
    Siamisang, Keatlaretse
    Rankgoane-Pono, Goabaone
    Madisa, Tumisang Malebo
    Mudiayi, Tantamika Kabamba
    Tlhakanelo, John Thato
    Mubiri, Paul
    Kadimo, Khutsafalo
    Banda, Francis Msume
    Setlhare, Vincent
    BMC PUBLIC HEALTH, 2022, 22 (01)
12345